The Strolling Poster sessions, take place during the following slots:
- July 15th 2025 from 17.30 to 19.00
- July 16th 2025 18.00 to 19.00
Posters are located in Poster Area inside the Boulevard Room (Boulevard Level). Poster Presenters have to attend for the whole duration of their session. It’s mandatory to respect the timing as detailed in the following scheme. Each poster presenter will be given 3 minutes to introduce the scientific paper, followed by a short discussion with the chairs. Posters are listed below alphabetically accordingly to first author. On each panel on-site you will find the Poster # as listed here. Please respect the poster # indications when you hang posters
Tuesday, 15th July 2025 from 17.30 to 19.00
Session 1: Basic Science
Chairs: W. Jin-fu (China) - Steven Taylor (USA)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 01 | 15/07/2025 | Benjamin Diggins (UK) | Benjamin Diggins (UK) | Anti-inflammatory and clinical effects of oral resveratrol supplementation in bronchiectasis |
| 02 | 15/07/2025 | Masaki Fujita (JPN) | Masaki Fujita (JPN) | Possible animal model of bronchiectasis? Chronic Pseudomonas aeruginosa infection provoked enlargement of small bronchus lumen in CCSP-deficient mice. |
| 03 | 15/07/2025 | Rebecca Hull (UK) | Rebecca Hull (UK) | Targeted Multiplex PCR for Characterising Infection Dynamics in Bronchiectasis |
| 04 | 15/07/2025 | Geonhui Min (KOR) | Geonhui Min (KOR) | Exploring Immune Dysfunction in Bronchiectasis: A Focus on Natural Killer Cells using Single-Cell Transcriptomes |
| 05 | 15/07/2025 | Patricia Namubiru (AUS) | Patricia Namubiru (AUS) | Functional and phenotypic neutrophil characteristics in bronchiectasis in adult humans. |
| 06 | 15/07/2025 | Shital Vishnu Patil (IND) | Shital Vishnu Patil (IND) | Microbiological and Pathophysiological Profile in Cases with Recurrent Exacerbation of Bronchiectasis: A Two-Center Experience |
| 07 | 15/07/2025 | Craig Schofield (AUS) | Craig Schofield (AUS) | A single cell RNA sequencing pipeline to assess airway inflammation using induced sputum samples from a prospective cohort of children with bronchiectasis |
| 08 | 15/07/2025 | Xiyue Shen (CHN) | Xiyue Shen (CHN) | First Nationwide Screening of Cystic Fibrosis Among Chinese Bronchiectasis Patients: Distinct Clinical and Genetic Profiles with Therapeutic Implications. |
| 09 | 15/07/2025 | Hans Van Der Wall (AUS) | Hans Van Der Wall (AUS) | Strong correlations between location of Bronchiectasis and scintigraphic sites of lobar pulmonary micro-aspiration of gastoesophageal refluxate |
| 10 | 15/07/2025 | Yimin Zhu (AUS) | Yimin Zhu (AUS) | Profiling DPP-1 signalling networks underlying lung immune defence |
Session 2: Comorbidities & Difficult Cases
Chairs: Wicki Basil (Switzerland) - Yong.hua Gao (China)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 11 | 15/07/2025 | William Flowers (UK) | William Flowers (UK) | Unmasking disease in ulcerative colitis-associated bronchiectasis after treatment with vedolizumab |
| 12 | 15/07/2025 | Shital Vishnu Patil (IND) | Shital Patil (IND) | Role of nebulised amikacin as an 'adjunct' to standard care in recurrent exacerbation Bronchiectasis during acute care hospitalization and follow-up period of 52 weeks: A two-tertiary care center study |
| 13 | 15/07/2025 | Louis Chai (SIN) | Louis Chai (SIN) | Bronchiectasis and Recurrent Infections in Thymoma Patients Attributable to Anti-Cytokine Autoantibodies |
| 14 | 15/07/2025 | William Good (NZL) | William Good (NZL) | Are we missing sinus disease in bronchiectasis? A sub-study of the Bactek-O trial. |
| 15 | 15/07/2025 | Paul Dawkins (NZL) | Dawkins Paul (NZL) | How do comorbidities affect outcomes in the New Zealand bronchiectasis population? |
| 16 | 15/07/2025 | Christine Lu (AUS) | Christine Lu (AUS) | Routine pathology testing prior to bronchoscopy: Limited clinical impact with significant economic and environmental costs |
| 17 | 15/07/2025 | Dilara O.topcu (TÜR) | Dilara O.topcu (TÜR) | Impact of the February 6,2023 Earthquake-Induced Environmental Pollution on Exacerbation Rates in Patients with Bronchiectasis |
| 18 | 15/07/2025 | Shital Vishnu Patil (IND) | Shital Patil (IND) | Clinical Benefit Analysis of Erdosteine plus azithromycin in comparsion to standard care in preventing exacerbation in recovered cases of acute exacerbation of Bronchiectasis: A long-term Comparative Efficacy Study |
| 19 | 15/07/2025 | Kirsty Watson (AUS) | Kirsty Watson (AUS) | The treatable traits approach is highly acceptable and a positive experience for patients in a regional Australian bronchiectasis outpatient clinic |
Session 3: Diversity
Chairs: Lucy Burr(Australia) - Charles Feldman (South Africa)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 20 | 15/07/2025 | Shereen Sharafaddin Alemam (SAU) | Shereen Sharafaddin Alemam (SAU) | Chronic Bronchiectasis Complicated by Common Variable Immunodeficiency (CVID): A Case Study of Multidisciplinary Management" |
| 21 | 15/07/2025 | Eleni Bacopanos (AUS) | Eleni Bacopanos (AUS) | Morbidity and mortality burden from bronchiectasis in the United Kingdom: An observational cohort study |
| 22 | 15/07/2025 | Subash Heraganahally (AUS) | Subash Heraganahally (AUS) | A clinical approach to the diagnosis and management of Bronchiectasis in adult Aboriginal patients in the Top End Northern Territory Australia |
| 23 | 15/07/2025 | Subash Heraganahally (AUS) | Heraganahally Subash (AUS) | Bronchiectasis Pocket Guide |
| 24 | 15/07/2025 | Jamie Felzer (UNI) | Jamie Felzer (UNI) | Sociodemographic Factors Associated with Health Outcomes in a Sample of the U.S. Bronchiectasis and Nontuberculous Mycobacteria Research Registry |
| 25 | 15/07/2025 | Timothy Howarth (AUS) | Timothy Howarth (AUS) | The Indigenous Bronchiectasis Assessment Scale - IBAS |
| 26 | 15/07/2025 | Shereen Sharafaddin Alemam (SAU) | Shereen Sharafaddin Alemam (SAU) | Comprehensive Diagnostic and Management Approach in a Case of Bilateral Bronchiectasis with Hemoptysis in a Heavy Smoker |
| 27 | 15/07/2025 | Eleni Bacopanos (AUS) | Eleni Bacopanos (AUS) | Bronchiectasis mortality trends across Europe between 2011 – 2018. |
| 28 | 15/07/2025 | Wei-jie Guan (CHN) | Weijie Guan (CHN) | Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis |
Session 4: Epidemiology & Registries
Chairs: Pamela J. Mcshane (USA) - Raja Dhar (India)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 29 | 15/07/2025 | Jacob Christensen (AUS) | Jacob Christensen (AUS) | Sunshine Coast Hospital and Health Service Bronchiectasis Registry: First local insights into an increasing healthcare burden |
| 30 | 15/07/2025 | Alexander Geyer (UNI) | Alexander Geyer (UNI) | Reproductive Lifespan and Post-menopausal Bronchiectasis in U.S. Postmenopausal Women: An investigation of the Women's Health Initiative Cohort |
| 31 | 15/07/2025 | George Solomon (UNI) | George Solomon (UNI) | Treatment patterns by exacerbation history in adults with bronchiectasis: data from the U.S. Bronchiectasis and NTM Research Registry |
| 32 | 15/07/2025 | Doreen Addrizzo-harris (UNI) | Doreen Addrizzo-harris (UNI) | U.S. BRONCHIECTASIS AND NTM CARE CENTER NETWORK: Improving the Diagnosis and Treatment of Bronchiectasis and Nontuberculous Mycobacterial Lung Disease |
| 33 | 15/07/2025 | Eunchae Kim (KOR) | Eunchae Kim (KOR) | Tailored AI Model for the Prediction of Severe Acute Exacerbation in an Asian |
| 35 | 15/07/2025 | Jack Roberts (AUS) | Jack Roberts (AUS) | Medicare and Pharmaceutical Benefit Scheme utilisation in Australians with Bronchiectasis: A report of linked data from the Australian Bronchiectasis Registry. |
| 36 | 15/07/2025 | Catherine Runge (AUS) | Catherine Runge (AUS) | Respiratory vaccination practices and infection experiences of Australian adults living with bronchiectasis |
| 37 | 15/07/2025 | Michal Shteinberg (ISR) | Michal Shteinberg (ISR) | Adults with paediatric-onset bronchiectasis (POBE) have greater disease severity compared to those with adult-onset bronchiectasis (AOBE): A multicenter EMBARC registry study |
| 38 | 15/07/2025 | Lidia Perea (ESP) | Lidia Perea (ESP) | The frequent exacerbator phenotype in bronchiectasis revisited: Data from the European Bronchiectasis Registry (EMBARC) |
| 40 | 15/07/2025 | George Solomon (UNI) | George Solomon (UNI) | The Impact of Proton Pump Inhibitor (PPI) Use on Exacerbation Rates in Patients with Bronchiectasis: An Analysis of the US Bronchiectasis and NTM Research Registry |
Session 5: Infections
Chairs: Gregory Tino (USA) - Francesco Blasi (Italy)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 41 | 15/07/2025 | Qaiser Akram (PAK) | Qaiser Akram (PAK) | Isolation of Multidrug Resistant Bacteria from hospitalized Bronchiectasis patients in Developing Countries |
| 42 | 15/07/2025 | Ophir Bar-on (AUS) | Ophir Bar-on (AUS) | The Impact of Nebulised Fucose/Galactose on Pseudomonas aeruginosa Airway Infection |
| 43 | 15/07/2025 | Subash Heraganahally (AUS) | Angelou Castro (AUS) | Respiratory viral pathogens during exacerbation of airway disease among adult Aboriginal Australians with bronchiectasis in the Top End Northern Territory Australia |
| 44 | 15/07/2025 | Subash Heraganahally (AUS) | Timothy Howarth (AUS) | Sputum antibacterial sensitivity and resistance patterns among adult Aboriginal Australians with Bronchiectasis in the Top End Northern Territory Australia |
| 45 | 15/07/2025 | Debora Kidanu (AUS) | Debora Kidanu (AUS) | Non-Cystic Fibrosis Bronchiectasis: Clinical Experience from Gold Coast University Hospital |
| 46 | 15/07/2025 | Emma Ledger (AUS) | Emma Ledger (AUS) | A paradoxical role of antibodies driving complement-mediated inflammation in Pseudomonas aeruginosa pulmonary infections |
| 47 | 15/07/2025 | Arjuman Sharmin (BAN) | Arjuman Sharmin (BAN) | Microbiological profile of sputum cultures in patients with severe bronchiectasis: a cross-sectional study |
| 48 | 15/07/2025 | Wei-jie Guan (CHN) | Weijie Guan (CHN) | Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis |
| 49 | 15/07/2025 | Kellie Strickland (AUS) | Kellie Strickland (AUS) | Population diversity and antimicrobial resistance profiling of Pseudomonas aeruginosa isolated from Australians with bronchiectasis |
| 50 | 15/07/2025 | Joshua Taverner (AUS) | Joshua Taverner (AUS) | Systematic review of clinical practice guidelines to identify vaccination recommendations for adults living with chronic lung disease |
| 51 | 15/07/2025 | Harry Thompson (UK) | Harry Thompson (UK) | Pushing the boundaries of virtual wards? Medication regimes traditionally considered high risk for home administration delivered safely via a virtual ward, and the potentially under-considered trauma of long inpatient stays |
| 52 | 15/07/2025 | Kazuya Tone (JPN) | Kazuya Tone (JPN) | Pulmonary nocardiosis with a nodular-bronchiectatic pattern: A potential cause and aggravator of bronchiectasis |
Session 6: NTM 1
Chairs: Stefano Aliberti (Italy) - Kozo Morimoto (Japan)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 53 | 15/07/2025 | Hind Al-abbasi (AUS) | Hind Al-abbasi (AUS) | The impact of the introduction of the Cepheid Xpert MTB/XDR on mycobacterium tuberculosis clinical management in Western Australia |
| 54 | 15/07/2025 | Melinda Ashcroft (AUS) | Melinda Ashcroft (AUS) | The rising incidence of nontuberculous mycobacterial infections in First Nations People in Queensland, Australia 2001–2024. |
| 55 | 15/07/2025 | Desilia Atikawati (IND) | Desilia Atikawati (IND) | Nontuberculous Mycobacterial Pleuritis in Congestive Heart Failure and Hypothyroid Patient |
| 56 | 15/07/2025 | Atsushi Funauchi (JPN) | Atsushi Funauchi (JPN) | Strain-Level Concordance Between Gastric Aspirate and Sputum Samples in Pulmonary Non-Tuberculous Mycobacterial Disease: A Retrospective Analysis |
| 57 | 15/07/2025 | Kazuki Hashimoto (JPN) | Kazuki Hashimoto (JPN) | Rapid and Comprehensive Identification of Nontuberculous Mycobacteria from Sputum: NALC-Seq |
| 58 | 15/07/2025 | Shaun Kang (AUS) | Shaun Kang (AUS) | Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease |
| 59 | 15/07/2025 | Daisy Lu (AUS) | Daisy Lu (AUS) | Epidemiology and clinical significance of NTM isolates at a tertiary centre in Victoria, Australia. |
| 60 | 15/07/2025 | Eriko Morino (JPN) | Eriko Morino (JPN) | Pulmonary NTM epidemiology in Japan-Analysis of Medical Claim from National Database 2012-2019 |
| 61 | 15/07/2025 | Kirby Patterson-fahy (AUS) | Kirby Patterson-fahy (AUS) | In vitro efficacy of sulbactam-durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates |
| 62 | 15/07/2025 | Dorothy Hui Lin Ng (SIN) | Dorothy Hui Lin Ng (SIN) | Supportive Care Gaps in Bronchiectasis Patients with NTM-PD: A Retrospective Study |
| 63 | 15/07/2025 | Kazuki Ono (JPN) | Kazuki Ono (JPN) | Characteristics and Prognosis in Patients with Bronchiectasis Receiving Long-Term Oxygen Therapy |
| 64 | 15/07/2025 | Jotam G. Pasipanodya (UNI) | Jotam Pasipanodya (UNI) | Role of Rifampin in the treatment of Pulmonary Mycobacterium avian Complex disease: a systematic review and analyses of target attainment |
Wednesday, 16th July 2025 from 18.00 to 19.00
Session 7: Microbiota
Chairs: Sanjay Chotirmall (India) - Jae-joon Yim (South Korea)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 01 | 16/07/2025 | Tim Baird (AUS) | Tim Baird (AUS) | Using Meta-Omics to Advance Precision-Based Bronchiectasis Management |
| 02 | 16/07/2025 | Ria Thompson (AUS) | Ria Thompson (AUS) | Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease |
| 03 | 16/07/2025 | Seung Won Ra (KOR) | Park Jinkyeong (KOR) | Bacterial Profiles in Inhaler Devices after 30 Days of Use by Patients with Non-Cystic Fibrosis Bronchiectasis |
| 04 | 16/07/2025 | Arjuman Sharmin (BAN) | Arjuman Sharmin (BAN) | Sputum microbiology in severe bronchiectasis: A cross-sectional study |
| 05 | 16/07/2025 | Wen-wen Wang (CHN) | Wen-wen Wang (CHN) | Pseudomonas aeruginosa-Driven Airway Dysbiosis and Machine Learning Prediction of Acute Exacerbations in Non-Cystic Fibrosis Bronchiectasis |
| 06 | 16/07/2025 | Ria Thompson (AUS) | Ria Thompson (AUS) | Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease |
| 07 | 16/07/2025 | Kazuma Yagi (JPN) | Kazuma Yagi (JPN) | The Impact of Microbiome on the Pathophysiology following Early-life Respiratory Syncytial Virus Infection |
Session 8: NTM 2
Chairs: Gregory Tino (USA) - Rachel Thomson (Australia)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 08 | 16/07/2025 | Stephanie Sutjipto (SIN) | Stephanie Sutjipto (SIN) | Management of Refractory Pulmonary Mycobacterium abscessus Infection in a Patient with Bronchiectasis: A Case Experience |
| 09 | 16/07/2025 | Shera Tan (SIN) | Shera Tan (SIN) | A case of Disseminated Mycobacterium Kansasii Infection with Interferon-ɣ Auto-antibodies |
| 10 | 16/07/2025 | Heeral Thakkar (AUS) | Heeral Thakkar (AUS) | Tigecycline Rechallenge for Pulmonary Mycobacterium abscessus Infection Following Hemorrhagic Pancreatitis: A Case Report |
| 11 | 16/07/2025 | Kirby Patterson-fahy (AUS) | Kirby Patterson-fahy (AUS) | Does lignocaine effect growth of nontuberculous mycobacteria? |
| 12 | 16/07/2025 | Fumiya Watanabe (JPN) | Fumiya Watanabe (JPN) | A pharmacokinetic-pharmacodynamic modeling approach to optimize ethambutol dosage based on in vitro time-kill assay against Mycobacterium avium |
| 13 | 16/07/2025 | Adrifen Berti Akbar (IND) | Adrifen Berti Akbar (IND) | Concurrent Malignant Pleural Mesothelioma with Pulmonary-Pleural Effusion Due to Non-Tuberculous Mycobacteria (NTM); a Rare Case Report |
| 14 | 16/07/2025 | Daniel Hicks (AUS) | Daniel Hicks (AUS) | Adverse events leading to Treatment Withdrawal and Interruption in Mycobacteroides abscessus pulmonary disease |
| 15 | 16/07/2025 | Hyung-jun Kim (KOR) | Hyung-jun Kim (KOR) | Clinical Significance of Discordant ESR and CRP Levels in Nontuberculous Mycobacterial Pulmonary Disease |
| 16 | 16/07/2025 | Youngmok Park (KOR) | Youngmok Park (KOR) | Adverse Drug Reactions During the Treatment of Nontuberculous Mycobacterial Pulmonary Disease: a Systematic Review and Meta-analysis |
Session 9: Paediatric
Chairs: Ahmad kantar (Italy) - Bernadette Prentice (Australia)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 17 | 16/07/2025 | Alana Ainsworth (NZL) | Alana Ainsworth (NZL) | Prospective ten year follow-up of an early intervention versus control study for children with severe bronchiolitis or pneumonia. |
| 18 | 16/07/2025 | Crystal Bourke (AUS) | Crystal Bourke (AUS) | Lung clearance index is more sensitive than spirometry to detect lung function impairment in children and adolescents with bronchiectasis |
| 19 | 16/07/2025 | Patrick Flume (UNI) | Patrick Flume (UNI) | Incidence and potential underlying aetiologies of paediatric bronchiectasis in the US: 2018–2022 |
| 20 | 16/07/2025 | Catherine Gilchrist (NZL) | Catherine Gilchrist (NZL) | BRONCHIECTASIS EXACERBATIONS IN CHILDREN: CAN HOSPITAL STAYS BE SHORTER? |
| 21 | 16/07/2025 | Grace Hendriks (AUS) | Grace Hendriks (AUS) | Bringing physiotherapy to First Nations children with chronic lung conditions in remote NT communities. |
| 22 | 16/07/2025 | Victoria Irons (NZL) | Victoria Irons (NZL) | Are we prescribing the correct antibiotics for positive respiratory cultures from our children with bronchiectasis? |
| 23 | 16/07/2025 | Catherine Byrnes (NZL) | Miriam Manga (NZL) | Koira4Rukahukahu: Lungs4Life: The development of a preventive program for chronic respiratory disease. |
| 24 | 16/07/2025 | Hannah O'farrell (AUS) | Hannah O'farrell (AUS) | Gene expression profiling of peripheral blood identifies systemic T-cell and neutrophilic immune response in paediatric bronchiectasis |
| 25 | 16/07/2025 | Laura Rensford (NZL) | Laura Rensford (NZL) | Physical Activity Levels in Children with Bronchiectasis Living in Counties Manukau, New Zealand. |
| 26 | 16/07/2025 | Kathy Rose (NZL) | Katherine Rose (NZL) | Are we completing the recommended first-line investigations for children with bronchiectasis at Starship Hospital? |
Session 10: PCD
Chairs: Claire Hogg (UK) - Catherine Byrnes (New Zealand)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 27 | 16/07/2025 | Lucy Morgan (AUS) | Megan Frohlich (AUS) | Seeing the Unseen: Regional Lung Function Assessment in PCD and non-PCD Bronchiectasis using a Novel XV Scanner |
| 28 | 16/07/2025 | Gil Herzberg (ISR) | Gil Herzberg (ISR) | Use of rhDNase in Primary Ciliary Dyskinesia Bronchiectasis |
| 29 | 16/07/2025 | Stephanie March (AUS) | Stephanie March (AUS) | From the Paddock to the Hospital Room: Raising a Child with Primary Ciliary Dyskinesia in Rural Australia |
| 30 | 16/07/2025 | Caitlin Meechan (AUS) | Caitlin Meechan (AUS) | Optimising Primary Ciliary Dyskinesia Screening in Adult Bronchiectasis. The value of nasal Nitric Oxide and PICADAR scoring. |
| 31 | 16/07/2025 | Felix C. Ringshausen (DEU) | Felix Ringshausen (DEU) | Creating evidence for the use of HypErtonic saLine in People with Primary Ciliary Dyskinesia – the multicenter, randomized, double-blind, crossover proof-of-concept clinical trial HELP-PCD |
Session 11: Physiotherapy & Allied Healthcare
Chairs: Rebecca Keating (Australia) - Annemarie Lee (Australia)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 32 | 16/07/2025 | Shereen Sharafaddin Alemam (SAU) | Shereen Sharafaddin Alemam (SAU) | Effectiveness of Airway Clearance Techniques in Bronchiectasis Management |
| 33 | 16/07/2025 | George Solomon (UNI) | George Solomon (UNI) | High frequency chest wall oscillation (HFCWO) data in the Bronchiectasis and Nontuberculous Mycobacteria (NTM) Research Registry (BRR) |
| 34 | 16/07/2025 | Carly Turner (AUS) | Carly Turner (AUS) | Feasibility of Electrical Impedance Tomography in assessing short-term effects of airway clearance techniques in adults with bronchiectasis, an observational study |
| 35 | 16/07/2025 | Tamara Lazzarin (AUS) | Tamara Lazzarin (AUS) | Healthcare access for children with bronchiectasis across an expansive geographical area: Analysis of inclusive paediatric physiotherapy service across metropolitan, regional and remote Queensland. |
| 36 | 16/07/2025 | Anmol Kaur Manjit Singh (MAL) | Singh Anmol Kaur Manjit (MAL) | Pulmonary Rehabilitation in Chronic Bronchiectasis: A Case Report on Sustained Improvements Through Individualized Therapy |
| 37 | 16/07/2025 | Jennifer Phillips (AUS) | Jennifer Phillips (AUS) | Active cycle of breathing technique, oscillating-PEP therapy or walking with huffing during a bronchiectasis exacerbation |
| 38 | 16/07/2025 | Mitchell Taylor (AUS) | Mitchell Taylor (AUS) | Effectiveness of a stepwise model of airway clearance techniques in bronchiectasis: a prospective cohort study |
| 39 | 16/07/2025 | Kirsty Watson (AUS) | Kirsty Watson (AUS) | The treatable traits approach is highly acceptable and a positive experience for patients in a regional Australian bronchiectasis outpatient clinic |
| 40 | 16/07/2025 | Carly Turner (AUS) | Carly Turner (AUS) | Web-based resources for healthcare professionals and individuals with bronchiectasis: A scoping review |
| 41 | 16/07/2025 | Elizabeth Webb (AUS) | Elizabeth Webb (AUS) | Exploring the barriers and enablers of airway clearance therapy and exercise amongst adults with bronchiectasis: a patient perspective |
Session 12: Treatments and New Drugs
Chairs: Lucy Morgan (Australia) - Jennifer Pollock (UK)
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 42 | 16/07/2025 | Tim Baird (AUS) | Tim Baird (AUS) | Efficacy, Safety, Cost and Antimicrobial Resistance Potential of Long-term Inhaled Colistimethate Sodium in Bronchiectasis: A Real-World Regional Australian Single-Centre Experience |
| 43 | 16/07/2025 | Timothy Aksamit (UNI) | Timothy Aksamit (UNI) | Lung Function in Patients With Non-Cystic Fibrosis Bronchiectasis By Prespecified Subgroups in the Phase 3, Randomized, Double-Blind, Placebo-Controlled Aspen Trial |
| 44 | 16/07/2025 | Gary Anderson (AUS) | Aowen Zhuang (AUS) | Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases |
| 45 | 16/07/2025 | Julia Bashford (AUS) | Julia Bashford (AUS) | CERTAIN Study: Ceftolozane/tazobactam continuous infusion for outpatient treatment of exacerbations of Cystic Fibrosis and Bronchiectasis |
| 46 | 16/07/2025 | William Flowers (UK) | William Flowers (UK) | Reducing the treatment burden for people with bronchiectasis: a protocol for deprescribing inhaled corticosteroids |
| 47 | 16/07/2025 | James D. Chalmers (UK) | James Chalmers (UK) | Efficacy of Brensocatib in Patients with Eosinophilic Inflammation in Bronchiectasis: An Analysis of the ASPEN Trial |
| 48 | 16/07/2025 | James D. Chalmers (UK) | James Chalmers (UK) | Results from a Phase II study (AIRLEAF®) of the dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in adults with bronchiectasis |
| 49 | 16/07/2025 | Presanth Nair Janathanan (AUS) | Presanth Nair Janathanan (AUS) | Barriers to Guideline-Directed Therapy for Stable Non- Cystic Fibrosis Bronchiectasis in Australia and New Zealand: A Narrative Review |
| 50 | 16/07/2025 | Kughanishah Jeyabalan (MAL) | Kughanishah Jeyabalan (MAL) | From Exacerbations to Relief: Harnessing Biologics in the Dual Challenge of Severe Asthma and Bronchiectasis |
| 51 | 16/07/2025 | Xue-shan Li (CHN) | Xue-shan Li (CHN) | Bacterial load, respiratory symptoms and inhaled antibiotic treatment in adults with bronchiectasis |
| 52 | 16/07/2025 | Wiebke Sauter (GER) | Wiebke Sauter (GER) | A Phase II study (CLAIRAFLY®) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in adults with cystic fibrosis bronchiectasis |
| 53 | 16/07/2025 | Katie Rice (AUS) | Katie Rice (AUS) | Impact of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on bone density in patients with Cystic Fibrosis: a retrospective study. |
| 54 | 16/07/2025 | George Solomon (UNI) | George Solomon (UNI) | Initial assessment of the "Chronic Airways Assessment Test" (CAAT™) as a drug development tool in bronchiectasis |
Session 13: Rising Stars & Oral Presenters
The WBC Chairs thank the Rising Stars and Oral Presenters: the following works will be displayed as Posters and discussed during the Plenary Sessions as stated in final programme booklet.
| Abs code | Date session | First Author | Presenter | Title |
|---|---|---|---|---|
| 01 | 16/07/2025 | James D. Chalmers (UNI) | Michal Shteinberg (UNI) | Study design of a Phase III study (AIRTIVITY®) of the novel dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in people with bronchiectasis |
| 02 | 16/07/2025 | Laura Ann Cooper (AUS) | Laura Cooper (AUS) | Economic evaluation of a physiotherapy-led community-based airway clearance service for people with chronic lung conditions: single group interrupted time series |
| 03 | 16/07/2025 | James D. Chalmers (UK) | James Chalmers (UK) | Safety and efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: Phase 1 results and Phase 2b trial design |
| 04 | 16/07/2025 | Robert Flowers (UNI) | Robert Flowers (UNI) | Racial and Ethnic Disparities in Bronchiectasis Outcomes in an Urban Safety-Net Hospital |
| 05 | 16/07/2025 | Kiyoharu Fukushima (JPN) | Kiyoharu Fukushima (JPN) | Molecular Epidemiological Surveillance for Non-Tuberculous Mycobacterial Pulmonary Disease: A Single Center Prospective Cohort Study. |
| 06 | 16/07/2025 | Koji Furuuchi (JPN) | Koji Furuuchi (JPN) | Gene Expression Profiling of Airway Epithelium in Mycobacterium avium Complex Lung Disease |
| 07 | 16/07/2025 | Rebecca Hull (UK) | Rebecca Hull (UK) | Airway Interleukin-7 is a biomarker of exacerbation risk in patients with Pseudomonas aeruginosa infection in bronchiectasis |
| 08 | 16/07/2025 | Merete Long (UK) | Merete Long (UK) | Results from the GREAT-2 phase II randomised placebo-controlled trial of the bispecific monoclonal antibody gremubamab targeting Pseudomonas aeruginosa in people with bronchiectasis |
| 09 | 16/07/2025 | Ellie Maas (AUS) | Ellie Maas (AUS) | Exome sequencing in a large cohort of primary ciliary dyskinesia: comprehensive evaluation of known genes and identification of new potential candidates |
| 10 | 16/07/2025 | Francesca Nicola (ITA) | Francesca Nicola (ITA) | Unraveling the pathogenicity of Mycobacterium abscessus in cystic fibrosis pulmonary epithelial cells and mouse models of respiratory infection. |
| 11 | 16/07/2025 | Lidia Perea (ESP) | Lidia Perea (ESP) | CC16 as a biomarker of bronchial infection and disease severity in bronchiectasis |
| 12 | 16/07/2025 | Jack Roberts (AUS) | Jack Roberts (AUS) | Development and validation of a bronchiectasis child-specific quality of life instrument: The BC-QoL |
| 13 | 16/07/2025 | Sarah Walker (AUS) | Sarah Walker (AUS) | Alpha-1 Antitrypsin Deficiency and Asthma: Modelling a Candidate Bronchiectasis Risk Nexus |
| 14 | 16/07/2025 | Lele Wang (CHN) | Le-le Wang (CHN) | Factors associated with hemoptysis in patients with non-cystic fibrosis bronchiectasis: cross-sectional analysis of data from the BE-China Registry |
| 15 | 16/07/2025 | Yingzhou Xie (CHN) | Yingzhou Xie (CHN) | Identification of a Response Regulator Controlling Antibiotic Persister Formation in Pseudomonas aeruginosa |
| 16 | 16/07/2025 | Ao Wen Zhuang (AUS) | Gary Anderson (AUS) | Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases |
POSTER PRESENTATIONS
Poster format & guidelines
- Suggested format for poster: A0 (width 84,1 cm x height 118,9 cm) or similar
- Orientation: portrait
- Authors are responsible for the printing of their poster in advance
- Please find here below one of the printing service company available onsite
Signarama South Brisbane – 35A Chorlton St – East Brisbane – Queensland 4169
Please have all print requests and files emailed latest 48 hours before the Conference starts to:
admin.southbrisbane@signarama.com.au
design.southbrisbane@signarama.com.au
Opening Hours:
Monday 7:30 am – 4:00 pm
Tuesday 7:30 am – 4:00 pm
Wednesday 7:30 am – 4:00 pm
Thursday 7:30 am – 4:00 pm
Friday 7:30 am – 3:00 pm
Schedule
- Posters can be set up on July 14, 2025, from 06.00 pm to 08.00 pm or on July 15 from 07.30 am to 08.30 am (before the beginning of the scientific sessions) and dismantled July 17, 2025, after 13.00. after this, all posters not yet removed will be destroyed.
- Please refer to the registration desk to know your emplacement. You will also find – at the entrance of the poster area – the “posters emplacement panel” with all the posters listed in alphabetical order, under poster presenter last name. Please display your poster on the poster board corresponding to the number indicated next to your poster title on the “posters emplacement panel”.
- The poster presenters are requested to stay next to their poster to illustrate it to the Committee and to reply to participants’ questions during the assigned poster session.
- Poster sessions’ schedule will be published on the congress final programme available on the website 10 days before the Conference.
- The posters will remain on display at BCEC from July 15 to July 17, 2025.
- Only the poster presenters attending the session will be eligible for poster prize.
- The winners will be chosen during the Conference and announced at the following session.
From Poster Award Winner to Conference Co-Chair: Prof. Felix C. Ringshausen’s WBC journey
purpose
You are invited to submit an abstract about research or a case report for topics related to Bronchiectasis, their causes, their comorbidities, their management and their evolution, for consideration as:
Poster Presentation
Topics
AATD
Alpha-1 Antitrypsin Deficiency
Basic Science
(aetiology & pathophysiology)
Comorbidities
(including non-pulmonary ones)
Diversity in Bronchiectasis
(comparison between different healthcare systems, comparison of diagnosis, management and treatment in different regions, or in different social classes, etc. or in different contest like city vs rural, comprehensive discussion of the management in specific Asian Pacific, African or South American country highlighting the pros and cons of the system, etc.)
Epidemiology & Registries
Infections
(including ABPA, Pseudomonas, Haemophilus, etc.)
Microbiota
and its interaction with lung health. Special focus on the interaction between the gut and lung microbiota and the effects of long-term antibiotics on the microbiota.
NTM
Nontuberculous mycobacteria
Paediatric Bronchiectasis
PCD
Primary Ciliary Dyskinesia
Pollution & Climate change
and their effects on Lung Health with a special focus on Bronchiectasis or NTM
Respiratory Physiotherapy & Airway Clearance / Nursing and Allied Healthcare experiences
Treatments and New Drugs
Tuberculosis & Bronchiectasis
THE CONCEPT
Accepted abstract presenters will have the opportunity to either:
- Display your poster in front of the international audience of more than 700 specialists.
- Discuss your work with the members of the scientific committee and the audience in the thematic poster sessions that will take place in the afternoon of July 15th and 16th.
- Compete for the best poster prizes. Winners will have their profile and work published on the congress website and will gain a free registration of the 9th World Bronchiectasis Conference in Hannover in June 2026.
Negotiations are in course to have all the accepted abstract published in special supplement of a renowned Journal in Respiratory Medicine.
GUIDELINES
Online submission
In order to participate in the selection process, please submit before June 6th, 2025.
Submit your work through the website selecting the section “Call for abstracts.”
Select the category “poster presentation”, select the topic among the list, follow the instructions and complete your submission according to the rules.
Upload a COI disclosure form.
General rules
Acceptance
Notifications to submitters will be sent by the middle of June 2025.
